Bone Health in Patients With Atopic Dermatitis

• ClinicalTrials.gov Identifier: NCT03800004
• Recruitment Status: Recruiting
• First Posted: January 10, 2019
• Last Update Posted: March 2, 2022
• Sponsor: Mayo Clinic
• Collaborator: Pediatric Dermatology Research Alliance
• Information provided by (Responsible Party): Megha M. Tollefson, M.D., Mayo Clinic

Study Description

Brief Summary:

This study examines the bone health in children with atopic dermatitis

Condition or disease
Atopic Dermatitis; Eczema

Detailed Description:

The goal of this study is to objectively evaluate bone health and contributing factors in children with AD. This will be compared with existing normative data. Such an objective prospective study, directly looking at bone health in children has not yet been done. This will be done using bone densitometry (DXA) and high-resolution peripheral quantitative computed tomography (HR-pQCT) for the accurate and precise measurement of bone health status. HR-pQCT is a cutting-edge technology available at only at a few academic centers in the United States that is used to measure bone strength with minimal doses of radiation. In addition, blood and urine metabolic parameters related to bone health will be analyzed, and data will be correlated with eczema severity. The results from this study will allow us to design large-scale, multi-institutional studies on bone health in this population and ultimately to guide decision making in children who may be at risk specifically regarding treatment recommendations and supportive care.

The specific aims of this project are:

1. To determine bone mineral density (BMD) and cortical and trabecular bone strength in children with atopic dermatitis, using DXA and to compare this with normative data.
2. HR-pQCT data will be compared with current known data from other diseases
3. To correlate bone mineral density with eczema severity using Eczema area and severity index (EASI) and Scoring atopic dermatitis (SCORAD) scores.
4. To determine if bone mineral density in children with atopic dermatitis correlates with bone age and bone-health specific serum markers.

Study Design

• Study Type: Observational
• Estimated Enrollment: 60 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Bone Health in Patients With Atopic Dermatitis
• Actual Study Start Date: July 30, 2018
• Estimated Primary Completion Date: December 30, 2022
• Estimated Study Completion Date: December 30, 2022

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. Correlate bone mineral density to normative data [ Time Frame: 2 years ]
   To determine bone mineral density (BMD) and cortical and trabecular bone strength in children with atopic dermatitis, using dual energy x-ray absorptiometry (DXA) and High-resolution peripheral quantitative computed tomography (HR-pQCT) and to compare this with normative data.
2. Correlate bone age with the Eczema area and severity index and the Scoring atopic dermatitis score [ Time Frame: 2 years ]
   To correlate bone mineral density with eczema severity using Eczema area and severity index (EASI) and Scoring atopic dermatitis (SCORAD) scores
3. Correlate bone age with serum markers [ Time Frame: 2 years ]
   To determine if bone mineral density in children with atopic dermatitis correlates with bone age and bone-health specific serum markers

Eligibility Criteria

• Ages Eligible for Study: 5 Years to 17 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Probability Sample

Study Population

Children with a diagnosis of moderate to severe atopic dermatitis as made by a dermatologist

Criteria

Inclusion Criteria:

• Children 5 to 17 years of age with a diagnosis of moderate to severe atopic dermatitis as made by a dermatologist
• Duration of atopic dermatitis symptoms for a minimum of 6 months
• Ability to cooperate with DXA and HR-pQCT procedure

Exclusion Criteria:

• Those without a confirmed diagnosis of moderate to severe atopic dermatitis
• Presence of concurrent disease that may also affect bone health, including rickets or other vitamin D deficiency, thyroid disease, renal disease, Paget's disease, osteogenesis imperfecta, inflammatory bowel disease, and other chronic inflammatory diseases
• Current use of medications that may affect bone health, including bisphosphonate, Forteo, Tymlos, denosumab, thiazide, heparin, medroxyprogesterone acetate, cyclosporine, and oral tacrolimus. However, medications that are used for atopic dermatitis treatment are allowed
• Pregnant or breast feeding females
• Inability to cooperate with the blood draw

Contacts and Locations

Contacts

Contact: Henry Nguyen, MD; 507-284-4673; Nguyen.Henry@mayo.edu

Contact: Katrina Pierce; 507-266-1078; Pierce.Katrina@mayo.edu

Locations

United States, Minnesota

Mayo Clinic; Recruiting

Rochester, Minnesota, United States, 55906

Contact: Henry Nguyen, MD 507-284-4673 Nguyen.Henry@mayo.edu

Contact: Katrina Pierce 507-266-1078 pierce.katrina@mayo.edu

Principal Investigator: Megha M Tollefson, MD

Sponsors and Collaborators

Mayo Clinic

Pediatric Dermatology Research Alliance

Investigators

• Principal Investigator: Megha M Tollefson, MD; Mayo Clinic
• Study Director: Henry Nguyen, MD; Mayo Clinic

More Information

Additional Information:

Mayo Clinic Clinical Trials 

Publications:

Garg N, Silverberg JI. Association between eczema and increased fracture and bone or joint injury in adults: a US population-based study. JAMA Dermatol. 2015 Jan;151(1):33-41. doi: 10.1001/jamadermatol.2014.2098.

Haeck IM, Hamdy NA, Timmer-de Mik L, Lentjes EG, Verhaar HJ, Knol MJ, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Low bone mineral density in adult patients with moderate to severe atopic dermatitis. Br J Dermatol. 2009 Dec;161(6):1248-54. doi: 10.1111/j.1365-2133.2009.09327.x. Epub 2009 Jun 4.

van Velsen SG, Knol MJ, van Eijk RL, de Vroede MA, de Wit TC, Lam MG, Haeck IM, de Bruin-Weller MS, Bruijnzeel-Koomen CA, Pasmans SG. Bone mineral density in children with moderate to severe atopic dermatitis. J Am Acad Dermatol. 2010 Nov;63(5):824-31. doi: 10.1016/j.jaad.2009.12.015. Epub 2010 Sep 17.

Wu CY, Lu YY, Lu CC, Su YF, Tsai TH, Wu CH. Osteoporosis in adult patients with atopic dermatitis: A nationwide population-based study. PLoS One. 2017 Feb 16;12(2):e0171667. doi: 10.1371/journal.pone.0171667. eCollection 2017.

• Responsible Party: Megha M. Tollefson, M.D., Principal Investigator, Mayo Clinic
• ClinicalTrials.gov Identifier: NCT03800004
• Other Study ID Numbers: 17-007112
• First Posted: January 10, 2019
• Last Update Posted: March 2, 2022
• Last Verified: February 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Megha M. Tollefson, M.D., Mayo Clinic:

Bone Health

Additional relevant MeSH terms:

Dermatitis, Atopic; Dermatitis; Eczema; Skin Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases